Seven cases of breast cancer recurrence limited to the central nervous system without other visceral metastases

Breast Cancer ◽  
2000 ◽  
Vol 7 (2) ◽  
pp. 153-156 ◽  
Author(s):  
Hisato Higashi ◽  
Takashi Fukutomi ◽  
Toru Watanabe ◽  
Isamu Adachi ◽  
Masaru Narabayashi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Cancer Recurrence ◽  
Breast Cancer Recurrence ◽  
Visceral Metastases ◽  
The Central Nervous System

History of Brain and Epidural Metastases from Breast Cancer in Relation with the Disease Evolution outside the Central Nervous System

1995 ◽  
Vol 35 (1) ◽  
pp. 38-42 ◽  
Author(s):  
S. Dethy ◽  
M.J. Piccart ◽  
M. Paesmans ◽  
P.V. van Houtte ◽  
J. Klastersky
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Disease Evolution ◽  
History Of ◽  
The Central Nervous System

scholarly journals Breast Cancer Metastasis to the Central Nervous System

2005 ◽  
Vol 167 (4) ◽  
pp. 913-920 ◽  
Author(s):  
Robert J. Weil ◽  
Diane C. Palmieri ◽  
Julie L. Bronder ◽  
Andreas M. Stark ◽  
Patricia S. Steeg
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Cancer Metastasis ◽  
Breast Cancer Metastasis ◽  
The Central Nervous System

scholarly journals The central nervous system can directly regulate breast cancer progression and blockage by quercetin

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Tianyu Luo ◽  
Yanmei Zhang ◽  
Xiaoyuan Liu ◽  
Qianyi Liang ◽  
Ling Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Cancer Progression ◽  
Breast Cancer Progression ◽  
The Central Nervous System

Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark

2017 ◽  
Vol 167 (2) ◽  
pp. 517-528 ◽  
Author(s):  
Deirdre Cronin-Fenton ◽  
Anders Kjærsgaard ◽  
Mette Nørgaard ◽  
Justyna Amelio ◽  
Alexander Liede ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Recurrence ◽  
Stage Ii ◽  
Breast Cancer Recurrence ◽  
Visceral Metastases

Aromatase Inhibitors: Clinical Pharmacology and Therapeutic Implications in Breast Cancer

1992 ◽  
Vol 20 (4) ◽  
pp. 303-312 ◽  
Author(s):  
N Pérez ◽  
J Borja
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Aromatase Inhibitors ◽  
Clinical Development ◽  
Breast Cancer Therapy ◽  
Therapeutic Implications ◽  
Adrenal Steroidogenesis ◽  
The Central Nervous System ◽  
Synthetic Glucocorticoids

Aminoglutethimide was the first aromatase inhibitor to be used in breast cancer therapy but, since it interacts with the synthetic glucocorticoids, hydrocortisone must also be given as a replacement. The most important side-effects of aminoglutethimide are at the level of the central nervous system. Other aromatase inhibitors with greater potency and selectivity are being developed. Pyridoglutethimide, a compound resulting from modifications to the structure of aminoglutethimide, seems to be devoid of sedative properties according to preliminary tests on the central nervous system. 4-Hydroxyandrostenedione is significantly more potent and better tolerated than aminoglutethimide. Fadrozole (CGS 16 949 A) is 200 – 400 times more potent than aminoglutethimide and is now in phase II of its clinical development. CGS 20 267 has no effect on adrenal steroidogenesis and is currently in phase I of its clinical development. Availability of newer aromatase inhibitors could make a worthwhile contribution to endocrine therapy in breast cancer.

scholarly journals Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1078
Author(s):  
Chikashi Watase ◽  
Sho Shiino ◽  
Tatsunori Shimoi ◽  
Emi Noguchi ◽  
Tomoya Kaneda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Central Nervous System ◽  
Nervous System ◽  
Radiation Therapy ◽  
Brain Metastasis ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Future Perspectives ◽  
Blood Brain ◽  
The Central Nervous System

Breast cancer is the second most common origin of brain metastasis after lung cancer. Brain metastasis in breast cancer is commonly found in patients with advanced course disease and has a poor prognosis because the blood–brain barrier is thought to be a major obstacle to the delivery of many drugs in the central nervous system. Therefore, local treatments including surgery, stereotactic radiation therapy, and whole-brain radiation therapy are currently considered the gold standard treatments. Meanwhile, new targeted therapies based on subtype have recently been developed. Some drugs can exceed the blood–brain barrier and enter the central nervous system. New technology for early detection and personalized medicine for metastasis are warranted. In this review, we summarize the historical overview of treatment with a focus on local treatment, the latest drug treatment strategies, and future perspectives using novel therapeutic agents for breast cancer patients with brain metastasis, including ongoing clinical trials.

Sign in / Sign up

Export Citation Format

Share Document